RarePipelinepeopleInnovationCollaborationCareersFinance Advance treatment Skip to main contentSkip to navigationSkip to search
Hansa Biopharma
HNSA (, %) SEK
Hansa Biopharma
Coffee and notepad

Press releases

2023

30 May 2023, 08:00
Hansa announces first patient dosed with imlifidase in a global pivotal phase 3 trial in anti-glomerular basement membrane (anti-GBM) disease
29 May 2023, 16:00 | Regulatory
Notice to Annual General Meeting in Hansa Biopharma AB (publ)
27 Apr 2023, 17:30
Hansa Biopharma and Genethon announce collaboration to develop imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies
20 Apr 2023, 08:00 | Regulatory
Hansa Biopharma interim report January–March 2023

· Positive reimbursement decision in Spain expands market access to include the five largest European markets
· Enrollment in phase 2 study of imlifidase in Guillain-Barré Syndrome (GBS) completed
· HNSA-5487: Phase 1 clinical study started in healthy volunteers
14 Apr 2023, 08:00
Hansa Biopharma to host conference call to provide interim results for January-March 2023 and a Business Update
31 Mar 2023, 08:00
Hansa Biopharma completes enrollment in phase 2 study of imlifidase in Guillain-Barré Syndrome (GBS)
30 Mar 2023, 08:00 | Regulatory
Hansa Biopharma publishes Annual Report 2022
29 Mar 2023, 15:00 | Regulatory
Hansa Biopharma announces positive reimbursement decision in Spain for Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized patients in kidney transplantation
Load more
Coffee and notepad

E-mail

Sign up to receive updates on the latest company news and filings

Choose type

Thank you. You will get an e-mail message to activate your subscription.